Vitek 2 MICs as first-line phenotypic screening method for carbapenemase-producing .
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Vitek 2 MICs as first-line phenotypic screening method for carbapenemase-producing .Published in
Future Microbiol 2021; 16(11):777-81PMID
34229445ae974a485f413a2113503eed53cd6c53
10.2217/fmb-2020-0024
Scopus Count
Collections
Related articles
- Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
- Authors: Iaconis JP, Pitkin DH, Sheikh W, Nadler HL
- Issue date: 1997 Feb
- Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Pseudomonas aeruginosa: Validation in a Multicenter German Cohort.
- Authors: Gill CM, Kresken M, Seifert H, Nicolau DP
- Issue date: 2021 Sep
- [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
- Authors: Metan G, Zarakolu P, Hasçelik G, Akova M
- Issue date: 2006 Jan-Apr
- Molecular surveillance of carbapenemase-producing Pseudomonas aeruginosa at three medical centres in Cologne, Germany.
- Authors: Schäfer E, Malecki M, Tellez-Castillo CJ, Pfennigwerth N, Marlinghaus L, Higgins PG, Mattner F, Wendel AF
- Issue date: 2019
- In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
- Authors: Hu YF, Liu CP, Wang NY, Shih SC
- Issue date: 2016 Aug 24